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1.

Introduction
Smoking is one of the most common risk factors for developing urothelial carcinoma (UC), including upper tract urothelial carcinoma (UTUC) [1] . Smoking increases the relative risk of developing this rare but potentially lethal disease by 2.5-to 7-fold [2] [3] [4] . One previous study of 502 UTUC patients showed that the risk of developing UTUC increases with an increasing number of daily smoked cigarettes and years of smoking, even when controlling for the effects of age and gender [5] . Smoking cessation >10 yr earlier seems to decrease the effect of smoking on UTUC development [5] .
Radical nephroureterectomy (RNU) with excision of a bladder cuff is the standard of care for patients with highgrade and/or invasive tumors of the renal pelvicalyceal system or ureters with a normal contralateral kidney [1, 6] . At the time of RNU, up to 50% of patients have nonorgan-confined disease or lymph node metastasis; 50-70% of these patients eventually die of UTUC within 5 yr of their RNU [6] [7] [8] . Cumulative evidence suggests an association between smoking and more advanced disease stage and grade as well as disease recurrence in urothelial carcinoma of the bladder (UCB) [9] [10] [11] [12] [13] . However, to the best of our knowledge, no study has yet assessed the impact of different aspects of smoking behavior on UTUC outcomes in patients treated with RNU.
We hypothesized that smoking is associated with biologically more aggressive tumors as reflected by pathologic features and survival outcomes. We also hypothesized that there is a dose-response relationship between smoking intensity and adverse outcomes and that smoking cessation may reduce these effects. To address these hypotheses, we investigated smoking habits and intensity as well as cessation from smoking in a large international multiinstitutional cohort of patients treated with RNU for UTUC.
2.
Patients and methods
Patient selection
This was a retrospective study approved by the institutional review board, with all participating sites providing the necessary data-sharing agreements prior to initiation. A total of five centers provided data. A computerized databank was generated for data transfer. After combining the data sets, reports were generated for each variable to identify data inconsistencies and other data integrity problems. Through regular communication with all sites, resolution of all identified anomalies was achieved before analysis. Prior to final analysis, the database was frozen. [14] . Hilar or regional lymphadenectomy was generally performed in patients with suspicious lymph nodes on preoperative imaging or with suspicious intraoperative findings [15] .
The indication and extent of lymphadenectomy performed was at the discretion of the individual surgeons. Tumor multifocality was defined as the synchronous presence of two or more pathologically confirmed tumors in any location (renal pelvicalyceal system or ureter). Adjuvant chemotherapy was administered at the investigator's discretion.
Pathologic evaluation
All surgical specimens were processed according to standard pathologic procedures at each institution. Genitourinary pathologists who were blinded to clinical outcomes reexamined all specimens according to standardized criteria and confirmed UC histology. [17] .
Histopathologic assessment included concomitant carcinoma in situ, tumor architecture (papillary or sessile based on the predominant feature of the index lesion [18] ), lymphovascular invasion (defined as the presence of tumor cells within an endothelium-lined space without underlying muscular walls [8] ), and tumor necrosis (defined as the presence of microscopic coagulative necrosis in >10% of the tumor [19] ).
Tumor location was defined as either renal pelvicalyceal or ureteral based on the index cancer [14] .
Smoking assessment
Smoking history was routinely assessed at a clinic visit within 1 yr of RNU.
Patients were only considered ever smokers if they had smoked 100 cigarettes during their lifetime. Data on self-reported cigarette smoking who quit smoking !10 yr prior to RNU did not differ from never smokers regarding advanced tumor stages, disease recurrence, and cancer-specific mortality, but they had better oncologic outcomes then current smokers and those patients who quit smoking <10 yr prior to RNU. The study is limited by its retrospective nature. Conclusions: Cigarette smoking is significantly associated with advanced disease stages, disease recurrence, and cancer-specific mortality in patients treated with RNU for UTUC. Current smokers and those with a heavy and long-term smoking exposure have the highest risk for poor oncologic outcomes. Smoking cessation >10 yr prior to RNU seems to mitigate some detrimental effects. These results underscore the need for smoking cessation and prevention programs. # 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Follow-up regimen
Patients were generally followed every 3-4 mo for the first year following RNU, every 6 mo from the second through the fifth year, and annually thereafter [6] . 
Results
Association of smoking with clinicopathologic characteristics
Of 864 patients, 244 (28.2%) never smoked, 297 (34.4%) were former smokers, and 323 (37.4%) were current smokers. Most of the former and current smokers smoked <20 CPD with a duration >20 yr. Among ever smokers, 87 (10.1%), 331 (38.3%), and 202 (23.4%) were light-short-term, moderate, and heavy-long-term smokers, respectively. Table 1 shows the descriptive characteristics of the study cohort. Current smokers were younger than former and never smokers (69 vs 71 and 70 yr, respectively; p = 0.025). Compared with never smokers, former and current smokers had higher tumor stages ( p < 0.001) and grades ( p = 0.009), more lymph node metastasis ( p < 0.001), and more tumor necrosis ( p = 0.048).
On logistic regression analyses, compared with never smokers, smoking status, quantity, duration, and cumulative exposure were all significantly associated with muscleinvasive disease and/or lymph node metastasis ( p values 0.004) and non-organ-confined disease and/or lymph node metastasis ( p values 0.022; Table 2 ). The odds of having advanced disease were highest among current smokers, as well as those smoking !20 CPD or with heavy-long-term cumulative exposure (Table 2 ). In the subgroup analyses of former smokers, smoking !20 CPD or having a heavy-long-term cumulative exposure was significantly associated with muscle-invasive disease and/or lymph node metastasis and non-organ-confined disease and/or lymph node metastasis ( p values 0.05). In subgroup analyses of current smokers, each stratification of smoking quantity, duration, and cumulative exposure was significantly associated with both end points compared with never smokers ( p values 0.015).
3.2.
Association of smoking with survival outcomes
Median follow-up of patients alive at censorship was 50 mo (interquartile range: 23-90). A total of 605 patients (70%) had >24 mo of follow-up available. During follow-up, disease recurred in 273 patients (31.6%), 359 (41.6%) died of any cause, and 220 (25.5%) died of UTUC. Actuarial recurrence-free survival estimates at 2, 5, and 10 yr after RNU were 69 AE 2% (standard error), 64 AE 2%, and 60 AE 2%, respectively. Actuarial cancer-specific survival estimates at 2, 5, and 10 yr after RNU were 79 AE 2%, 69 AE 2%, and 62 AE 2%, respectively. Current and former smokers had a higher risk of disease recurrence ( p values 0.016) and cancer-specific mortality compared with never smokers ( p values 0.005; Fig. 1 ). In addition, current smokers had a higher risk of disease recurrence ( p = 0.017) compared with former smokers. Light-short-term, moderate, and heavy-long-term smokers had higher risks of disease recurrence compared with never smokers ( p values 0.033; Fig. 2 ). Heavy-long-term smokers had a higher risk of cancer-specific mortality compared with never smokers ( p value <0.001), as well as a higher risk for both end points compared with moderate smokers ( p values 0.031). There was no difference between light-short-term and moderate smokers and, interestingly, light-short-term and heavy-long-term smokers for both end points (Fig. 2) .
In the subgroup of former smokers, heavy-long-term smokers had a significantly higher risk for both end points compared with never, light-short-term, and moderate smokers ( p values 0.034), who in turn were not different from each other ( p > 0.05). In contrast, in the subgroup of current smokers, light-short-term, moderate, and heavylong-term smokers had a significantly higher risk for both end points compared with never smokers ( p 0.011). Light-short-term, moderate, and heavy-long-term smokers were not significantly different from each other in this subgroup. When analyzing patients according to smoking quantity and duration separately, those who smoked !20 CPD or !20 yr had a higher risk for both end points compared with never smokers ( p values 0.002).
On multivariable analyses that adjusted for the effects of standard clinicopathologic parameters, current smoking status was associated with disease recurrence (hazard ratio [HR]):1.66; 95% confidence interval [CI], 1.18-2.34; p = 0.003) and cancer-specific mortality (HR: 1.54; 95% CI, 1.00-2.07; p = 0.05; Table 3a ). In addition, former smokers had a significantly higher risk of cancer-specific mortality (HR: 1.48; 95% CI, 1.01-2.17; p = 0.044). Compared with never smokers, smokers with !20 CPD, !20 yr of smoking, or heavy-long-term smokers had a significantly higher former smokers) prior to RNU. Compared with never smokers, current and recent former smokers had increased risks of muscle-invasive, non-organ-confined disease, or lymph node metastasis on multivariable analyses that adjusted for the effects of age, gender, and tumor location ( p values<0.001; Table 2 ). The cumulative incidences of disease recurrence and cancer-specific mortality according to smoking status and time since cessation are shown in Figure 3 . There was no difference in outcomes for both end points between current and recent former smokers as well as between never and distant former smokers ( p values >0.05). Current smokers and recent former smokers had a significantly higher risk of disease recurrence and cancer-specific mortality than never smokers ( p values 0.011). Smoking cessation was not associated with disease recurrence or cancer-specific mortality on multivariable analyses ( p values >0.05).
To elaborate the association of time from cessation and cumulative smoking intensity, we stratified former smokers by both variables. Of the 297 former smokers, all light smokers (66 [22.2%]) were distant former smokers, all moderate smokers (126 [42.4%]) were recent former smokers, and there were 105 heavy smokers (35.4%). Of these heavy smokers, 27 (9.1%) quit >10 yr and 78 (26.3%) <9.9 yr prior to RNU. Using never smokers as a reference group in univariable Cox regression analyses, light former smokers had a reduced risk of disease recurrence (HR: 0.67) and cancer-specific mortality (HR: 0.55). For both end points, these odds increased for moderate smokers (HRs: 1.17 and 1.18, respectively), distant former heavy smokers (HRs: 1.92 and 2.69, respectively), and recent former heavy smokers (HRs: 2.19 and 2.69, respectively).
Discussion
Almost two thirds of patients in our study were current or former smokers, underscoring the close association of cigarette smoking and the development of UTUC [5] . Cigarette smoking is an established risk factor for the development of UC of both the upper and lower urinary tract [2, 23] . There is little knowledge regarding the effect of smoking on UTUC progression and outcomes, however. A better understanding of these associations could offer insights into the natural history of UTUC, as well as improve patient counseling and possibly outcomes through modification of smoking habits. We found that current smokers were at a significantly higher risk of advanced disease stages and lymph node metastasis compared with never smokers. Current smokers had a higher risk of disease recurrence as well as current and former smokers for cancer-specific mortality. The odds of having advanced disease and the likelihood of disease recurrence and cancer-specific mortality increased progressively from never to former to current smokers. Similar findings have previously been reported in other urologic malignancies such as prostate and renal cell cancer [10, 25] . However, the magnitude of the odds was higher for standard clinicopathologic features than for smoking, which is similar to previous findings in UCB [26] . The failure to find a statistical significant association between 6 3 ( 2 0 1 3 ) 1 0 8 2 -1 0 9 0 former smoking status and disease recurrence in multivariable analyses might be explained due to the strength of the covariables (ie, pathologic stage, grade, and lymph node status), which are established predictors of outcomes, as confirmed in our study [6, 8, 27] . In addition, controlling for intermediate variables (such as clinicopathologic variables) can result in overadjustment that usually biases estimates toward the null [28] .
We found a dose relationship between cumulative smoking exposure and risk of developing advanced disease stages and poor outcomes. Although never smokers had the most favorable outcomes, heavy-long-term smokers had the worst. Heavy-long-term cumulative smoking exposure was an independent risk factor for features of biologically aggressive UTUC (ie, advanced disease stages and lymph node metastasis) as well as disease recurrence and cancerspecific mortality after adjusting for the effects of established features. Indeed, the odds for each end point were highest in heavy-long-term smokers. In addition, patients with the highest smoking quantity and duration presented with the worst outcomes. Although there is no comparable study in UTUC, similar findings have been reported in UCB [10, 12] . Two large studies found that stage and grade increased according to smoking status and with increasing quantity of smoking. Although the exact mechanisms of smoking-induced urothelial carcinogenesis remain unknown, accumulating evidence suggests that dose escalation and longer duration might increase not only the risk of development of UC but also its aggressiveness and the risk of progression to advanced disease [2, 11, 12, 23] . We found that smoking cessation >10 yr seemed to mitigate the unfavorable effects of smoking in UTUC patients. Distant former smokers had less advanced disease stages, fewer disease recurrences, and lower cancer-specific mortality compared with recent former or current smokers. This beneficial effect in patients with long-term smoking cessation may be due to minor field damage effects or better retained repair mechanisms [21, 26] . Although our results confirmed the need of long-term smoking cessation to reduce the effect of smoking in UC [2, 21, 26] , this effect was not present in all former smokers. Smoking intensity seems to have an important impact on outcomes; a combination of smoking with other inherent/genetic, environmental, behavioral, or lifestyle factors that our study could not adjust for might be another explanation [29] .
Our study has several limitations. First and foremost are limitations inherent to the retrospective and multiinstitutional nature of the study including surgeons' numbers, preferences, experience, and caseload, as well as surgical techniques. Absence of lymphadenectomy in a significant number of patients as well as differences in the lymph node count and anatomic template of lymphadenectomy might have influenced our results. Another limitation includes possible interobserver variability between pathologists; a central pathology review was not performed. However, all surgeons and pathologists operated at centers dedicated to the management of UTUC. Comorbidities might have influenced the decision making regarding surgical therapy, introducing a selection bias. Another bias might be the exclusion of tobacco products other than cigarettes (eg, cigars, pipes, tobacco chewing) and different forms of tobacco exposure (eg, secondhand smoking, occupational exposure). We could also not adjust our analyses for different types of tobacco and its constituents. Finally, smoking history was self-reported and therefore subject to recall bias.
Conclusions
Cigarette smoking is significantly associated with advanced disease stages, lymph node metastasis, disease recurrence, and cancer-specific mortality in patients treated with RNU for UTUC. Current and heavy-long-term smokers have the highest risk for poor outcomes. Smoking cessation >10 yr prior to surgery seems to reduce the unfavorable effects of smoking on outcomes. Although our results need to be confirmed in a robust prospective study, these findings should further help urologists and general health care practitioners to counsel their patients regarding the benefits of smoking cessation and prevention programs.
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